

Please try another search
Investing.com - Curaleaf slumped in midday trade Tuesday after receiving a warning letter from the Federal Drug Administration over its promotion of unapproved products containing cannabidiol (CBD).
The cannabis operator has 15 days to submit a written plan to address the violations.
Curaleaf (OTC:CURLF) fell 6.3%, while Aurora Cannabis (NYSE:ACB) slipped 1.5% and Canopy Growth (NYSE:CGC) was flat.
The FDA letter says the company’s products are unapproved drugs and the company has claimed on its website and social media accounts that its CBD products soothe chronic pain and relieve anxiety.
CBD has exploded in popularity as it lacks the psychoactive properties of THC. The FDA is still creating clearer guidelines for CBD, which it considers a drug.
(Reuters) - The S&P 500 and the Nasdaq fell after the opening bell on Wednesday, after several policymakers made a case for faster interest rate hikes to tamp down inflation as a...
By Senad Karaahmetovic Morgan Stanley analysts shared insights from the latest work-from-home (WFH) survey. The results signal “durable firewall demand as enterprises secure...
By Senad Karaahmetovic Shares of Bed Bath & Beyond (NASDAQ:BBBY) are down almost 15% in pre-open Wednesday after the company reported a much wider-than-expected Q1 loss. BBBY...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.